Ramos, Mafalda http://orcid.org/0000-0002-8472-3841
Men, Peng
Wang, Xu
Ustyugova, Anastasia
Lamotte, Mark
Funding for this research was provided by:
Boehringer Ingelheim International GmbH
Article History
Received: 4 March 2021
Accepted: 19 July 2021
First Online: 4 August 2021
Declarations
:
: Not applicable.
: Not applicable.
: MR, ML are full time employees of IQVIA. IQVIA received consulting fees from Boehringer Ingelheim to conduct this work. AU and XW are full-time employees of Boehringer Ingelheim, the manufacturer of empagliflozin. PM declares no conflict of interest.